An observational study in Pancreas Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Ludwig-Maximilians - University of Munich. Terminated at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Ludwig-Maximilians - University of Munich · Observational
Enrollment stopped early on May 31, 2024, because of slow accrual, an unexpectedly high rate of postoperative drop-out and a low rate of ctDNA-positive patients.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 175 studies in Pancreatic Neoplasms with a site in Germany — 24 open to participants now, 35 under way, 10 of them phase 3. Pancreatic Neoplasms · Germany.
Among the 175 studies in Pancreatic Neoplasms with a site in Germany, this one is the 23rd largest by enrollment of the 29 observational ones that give a count, is one of 14 that started in 2020, is one of 29 observational ones, and was the 123rd registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →24 of the 175 studies in Pancreatic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Germany, United States, Belgium and 10 more countries
Ages 18+
Immuneering Corporation · Sites in Germany, United States, Australia and 6 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Germany, Switzerland
Ages 18+
Incyte Corporation · Sites in Germany, United States, Australia and 19 more countries
Ages 18+
Revolution Medicines, Inc. · Sites in Germany, United States, Australia and 18 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
175 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 69 · Phase 3 44
First in 1997; this study’s year is marked. 14 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is below the median of 200 across 743 observational studies indexed under Pancreatic Neoplasms.
Median enrollment 122 across the 143 interventional studies, 338 across the 29 observational. Of the 118 that completed or were terminated, 38 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 175 have an industry lead sponsor. The 10 most frequent:
Ludwig-Maximilians - University of Munich is the lead sponsor of 223 studies on the registry; 29 are open to participants now.
Ludwig-Maximilians - University of Munich has 3 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Pancreatic Neoplasms with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02912949Partner Therapeutics, Inc.A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | 2026-12-31 |
| NCT04421820Bold Therapeutics, Inc.BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours | 2027-07-01 |
| NCT07280377Oncolytics BiotechA Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 175 studies in Pancreatic Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PROJECTION is a non-randomized, multicenter, non-interventional cohort study in patients with resectable pancreatic ductal adenocarcinoma (PDAC). Patients are allocated to two observation groups according to the preoperative presence (Group A) or absence (Group B) of circulating tumor DNA (ctDNA) in a liquid biopsy analyzed with FoundationOne Liquid CDx. After surgery and completion of local histological evaluation, tumor tissue is analyzed with FoundationOne CDx. Earlier protocol versions also included a second liquid biopsy within 14 days before the start of adjuvant chemotherapy. Patients are followed for recurrence according to institutional standards about every three months for the first 18 months after surgery and about every six months thereafter, until recurrence or death, for a maximum of 36 months after surgery and until May 31, 2025 at the latest. Enrollment was stopped on May 31, 2024.
Patients with pancreatic mass, suspicious of pancreatic cancer and deemed resectable will be prospectively enrolled in this observational study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients are allocated to group A according to preoperative presence of detectable ctDNA.
Diagnostic Test: FoundationOne Liquid CDx · Diagnostic Test: FoundationOne CDx
Patients are allocated to group B according to preoperative absence of detectable ctDNA.
Diagnostic Test: FoundationOne Liquid CDx · Diagnostic Test: FoundationOne CDx
Liquid biopsy of about 17-20 ml peripheral blood within 7 days (in exceptional cases 14 days) before surgery; analysis of circulating tumor DNA with FoundationOne Liquid CDx. Results were not reported to investigators and did not influence treatment.
Genomic profiling of formalin-fixed, paraffin-embedded tumor tissue from the resection specimen with FoundationOne CDx.
Disease-free survival (DFS)
Comparison of disease-free survival (DFS) between patients with preoperative presence (Group A) and absence (Group B) of circulating tumor DNA. DFS is the time from surgery to local recurrence, distant metastasis or death from any cause, whichever comes first.
Time frame: From surgery until recurrence or death, up to 36 months after surgery and no later than May 31, 2025
DFS by tumor mutational status
DFS in Groups A and B according to the mutational status of the resected tumor tissue determined with FoundationOne CDx
Time frame: From surgery until recurrence or death, up to 36 months after surgery and no later than May 31, 2025
DFS by clinical parameters
DFS in Groups A and B according to clinical parameters
Time frame: From surgery until recurrence or death, up to 36 months after surgery and no later than May 31, 2025
Overall survival (OS)
Time from surgery to death from any cause, compared between Groups A and B
Time frame: From surgery until death or end of observation, no later than May 31, 2025
Plan to share: Yes — Anonymized individual participant data are available on reasonable request to the corresponding author after review by the study leadership and under a data use agreement.
No publications or documents are linked to this record.
Ran from Dec 2020 to primary completion in Jun 2025, 53 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Dec 2021 → Dec 2020, primary completion Dec 2025 → Jun 2025 and completion Dec 2026 → Jun 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Enrollment stopped early on May 31, 2024, because of slow accrual, an unexpectedly high rate of postoperative drop-out and a low rate of ctDNA-positive patients.
Enrollment stopped early on May 31, 2024, because of slow accrual, an unexpectedly high rate of postoperative drop-out and a low rate of ctDNA-positive patients.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ludwig-Maximilians - University of Munich →